Pfizer (PFE) Work In Process (2009 - 2019)

Pfizer (PFE) has reported Work In Process for 11 consecutive years, with $5.2 billion the latest figure, recorded in Q1 2019.

• On a quarterly basis, Work In Process rose 15.54% year-over-year to $5.2 billion in Q1 2019; TTM through Mar 2019 was $5.2 billion, a 15.54% increase from a year earlier, with the FY2018 full-year figure at $4.7 billion, up 20.29% from the prior year.
• Work In Process was $5.2 billion for Q1 2019 at Pfizer, up from $4.7 billion in the prior quarter.
• Over five years, Work In Process peaked at $5.2 billion in Q1 2019 and troughed at $3.4 billion in Q1 2015.
• A 5-year average of $4.1 billion and a median of $4.0 billion in 2016 frame the typical range for Work In Process.
• Across the five-year window, Work In Process gained 21.06% in 2015 and slipped 6.0% in 2016, its largest moves.
• Over 5 years, Work In Process stood at $3.9 billion in 2015, then slipped by 6.0% to $3.7 billion in 2016, then rose by 5.74% to $3.9 billion in 2017, then advanced by 20.29% to $4.7 billion in 2018, then rose by 10.23% to $5.2 billion in 2019.
• The last three Work In Process figures came in at $5.2 billion (Q1 2019), $4.7 billion (Q4 2018), and $4.8 billion (Q3 2018), per Business Quant data.